Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

Focused Ultrasound with Low-Dose Gemcitabine to Increase Immune Control in Patients with Stage I-III Breast Cancer

Trial Status: closed to accrual

This phase I trial studies the side effects of focused ultrasound with low-dose gemcitabine in increasing immune control in patients with stage I-III breast cancer. Highly focused ultrasound energy may kill tumor cells by heating them to several degrees above normal body temperature without affecting the surrounding tissue. Chemotherapy drugs, such as gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This study may help researchers determine if focused ultrasound with or without gemcitabine could help treat breast cancer when they are given before surgery.